Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-078568·Enliven Therapeutics, Inc.
Schedule 13G ownership disclosure
Enliven Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 29337E102
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLC
Shares: 3,711,444.00 · Class: 6.3%
- Fairmount Healthcare Fund II L.P.
Shares: 3,711,444.00 · Class: 6.3%
- Peter Harwin
Shares: 3,711,444.00 · Class: 6.3%
- Tomas Kiselak
Shares: 3,711,444.00 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-078568
- Form type
- SCHEDULE 13G/A
- Filer
- Enliven Therapeutics, Inc.
- CIK
- CIK 1672619
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership